Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	31.37B
Revenue (ttm)	12.57B
Net Income (ttm)	2.19B
Shares Out	n/a
EPS (ttm)	2.38
PE Ratio	14.30
Forward PE	n/a
Dividend	1.48 (5.32%)
Ex-Dividend Date	Jul 8, 2024

Volume	1,968,484
Average Volume	1,007,584
Open	27.60
Previous Close	27.95
Day's Range	27.20 - 28.10
52-Week Range	23.10 - 34.00
Beta	0.27
RSI	65.76
Earnings Date	Mar 27, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY